Plain Language Summary: Results from the MSBase registry looking at the effectiveness of cladribine tablets for multiple sclerosis
This Plain Language Summary of Publication from Neurodegenerative Disease Management summarises results from the MSBase registry. The MSBase registry contains information from over
80,000 people living with multiple sclerosis (MS). Using this information a study called GLIMPSE was carried out. The study found real-life outcomes in people living with MS who were treated with cladribine tablets (Mavenclad®) compared with other oral treatments.
Read the full article here.
The original article on which this summary is based was published in Multiple Sclerosis Journal. The original article is called ‘Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry’. You can read it here.